Researchers suggest inhibiting TGM2 could treat GBM

In a paper published in Cancer Research, researchers at the Korean National Cancer Center and colleagues showed that inhibiting transglutaminase 2 (TGM2; TG2) prevents mesenchymal transition of glioma stem cells and could be used to treat glioblastoma multiforme (GBM).

Transdifferentiation of epithelial to mesenchymal cells is associated with the mesenchymal subtype of glioblastoma, and has been linked to poor prognosis in glioblastoma patients. In the paper, the authors showed that TGM2 expression was higher in glioma stem cells of recurrent mesenchymal glioblastoma patients and correlated with poorer prognosis compared to patients with initial mesenchymal or non-mesenchymal glioblastoma, suggesting that TGM2 induces mesenchymal transdifferentiation and glioblastoma progression...